Biotechnology

Palatin Tech

Palatin Tech released FY2026 Q3 earnings on May 13 After-Market (EST), actual revenue USD 3.921 M (forecast USD 1.283 M), actual EPS USD -0.3699 (forecast USD -1.2433)

Palatin Tech released FY2026 9 Months earnings on May 13 After-Market EST, actual revenue USD 12.88 M, actual EPS USD 1.0297

Palatin Tech released FY2026 Semi-Annual Earnings on February 17 During-Market EST, Actual Revenue USD 8.964 M, Actual EPS USD -1.4731

Palatin Tech released FY2026 Q2 earnings during market hours on February 17 (EST), actual revenue USD 116.04 K (forecast USD 16.67 K), actual EPS USD -2.8602 (forecast USD -2.3533)

Palatin Tech to Release FY2026 Semi-Annual Earnings on February 17, 2026, During Market Hours (EST)

Palatin Tech released FY2026 Q1 earnings on November 14 During-Market EST, actual revenue USD 8.848 M, actual EPS USD 4.2599

Palatin reports Q1 2026 financial results and completes public offering

Palatin Tech released FY2025 Q4 earnings on September 23 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.7236 (forecast USD -9.5)

Palatin Tech released FY2025 Annual Earnings on September 23 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -32.1489 (forecast USD -49.5)

Palatin Technologies Announces Positive Preclinical Results for PL7737

Palatin Technologies Inc. amends its charter to issue new shares

Palatin Technologies Reports Q3 2025 Earnings, Net Loss Decreases

Palatin Tech released FY2025 Q3 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -9.1317 (forecast USD -8.5)

Palatin Tech released FY2025 9 Months Earnings on May 14 (EST), Actual Revenue: USD 0, Actual EPS: USD -34.7618

Palatin Technologies to Update on Obesity and Ophthalmology Project Progress

Palatin Technologies Inc. Reports Q1 2025 Net Loss of $4.8 Million

Director Robert K. DeVell Jr. Acquires Shares in Palatin Technologies

Palatin Technology Presents Phase III Data for Dry Eye Treatment PL9643

Palatin Technologies Announces Public Offering Pricing Expected to Raise $23 Million

Palatin Announces Promising Preclinical Data for GLAUCOMA Therapy PL9588

Liminatus Pharma

Agape ATP

Co-Diagnostics

NewGenIvf

Tradr 2X Long RGTI Daily ETF

Sunshine Biopharma

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long QBTS Daily ETF

Wheeler Real Estate

Defiance 2X Daily Long Pure Quantum ETF

Palatin to Begin Trading on Nasdaq Stock Exchange | PTN Stock News

StockTitan

PALATIN TECHNOLOGIES INC

Corgi Ip Licensing & Royalties ETF

Palatin to Begin Trading on Nasdaq Stock Exchange | PTN Stock News

Earnings Watch

Palatin Tech | 10-Q: FY2026 Q3 Revenue: USD 3.921 M

SBIO

ARKG

LABU

Palatin Technologies shares are trading higher after the company reported better-than-expected Q1 EPS results.

benzinga_article

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

VG Health

iShares US Pharma

iShares Global Healthcare

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

LABD

Palatin shares are trading lower. The company reported its Q3 financial results.

Direxion S&P Biotech Bear 3X

XDAT

DTCR

IDGT

CLOU

SRVR

Dynatrace (NYSE:DT) reported strong Q4 2026 earnings, surpassing $2 billion in ARR with a consistent 16% growth for the fourth consecutive quarter. Key highlights include a 100% growth in their logs segment, the launch of Dynatrace Intelligence, and strategic acquisitions like Dev Cycle and Bindplane. The company anticipates ARR growth of 15.5% to 16.5% in fiscal 2027, supported by strong demand for AI-powered observability. Operationally, Dynatrace secured 22 contracts over $1 million in ACV and achieved a free cash flow margin of 26%.

Dynatrace

iShares Expanded Tech Software Sector ETF

Proshares Big Data Refiners ETF

ISHRS S&P Glb It

Franklin Exponential Data ETF

Global X Data Center & Dgtl Infrs ETF

iShares US Digital Infrastructure and Real Estate ETF

SPDR S&P Software

Global X Cloud Computing ETF

Pacer Data & Infrastructure Real Estate ETF

ServiceNow

Transcript: Dynatrace Q4 2026 Earnings Conference Call

Palatin Technologies, Inc. reported its fiscal third quarter 2026 financial results, focusing on advancing MC4R-based obesity programs targeting rare disorders. Key developments include a once-weekly injectable MC4R selective peptide agonist on track for IND submission in Q4 2026 and a next-generation oral candidate aimed for submission in H1 2027. The company also announced partnerships for retinal diseases and dry eye disease, enhancing its financial position. A conference call is scheduled for May 13, 2026, to discuss these updates further.

Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update | PTN Stock News

Patronus Resources has confirmed broad gold anomalies at its Pine Creek Project in the Northern Territory, following infill surface sampling across a 400m by 100m grid. The results, based on 5,518 samples, highlight significant exploration potential in the Northern Leases and Grove Hill areas. This development positions Patronus for follow-up drilling and exploration, enhancing the strategic value of its holdings. The current analyst rating for Patronus Resources (AU:PTN) is a Hold, with a price target of A$0.07.

Tip Ranks

Patronus Resources Confirms Broad Gold Anomalies at Pine Creek Project

Palatin Tech(PTN.US)

Palatin to Begin Trading on Nasdaq Stock Exchange | PTN Stock News

Palatin Tech | 10-Q: FY2026 Q3 Revenue: USD 3.921 M

Palatin Technologies shares are trading higher after the company reported better-than-expected Q1 EPS results.

Palatin shares are trading lower. The company reported its Q3 financial results.

Transcript: Dynatrace Q4 2026 Earnings Conference Call

Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update | PTN Stock News

Patronus Resources Confirms Broad Gold Anomalies at Pine Creek Project